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Population aging and osteoporosis are global public health challenges. Osteoporosis markedly increases
the risk of fractures, and further morbidity and mortality. Calcium is a major constituent of the bone and
vitamin D helps maintain calcium homeostasis. Calcium and vitamin D supplements have long been
recognized as the cornerstones for prevention and management of osteoporosis and fractures. Although
the associations between calcium and vitamin D supplementation and bone mineral density, fracture
prevention, and potential adverse outcomes from available evidence are inconsistent, the Institute of
Medicine Committee and the American Geriatrics Society support a key role of calcium and vitamin D in
skeletal health. There is insufﬁcient evidence to conclude that calcium with or without vitamin D sup-
plementation increases the risk of cardiovascular events and cancer. Older adults should obtain at least
1000 IU/day of vitamin D with 1000e1200 mg/day of calcium to reduce the risk of fractures. The actual
supplementation levels of calcium and vitamin D should be advised individually to speciﬁc patient or
situation.
Copyright © 2014, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Population aging is a phenomenon that occurs worldwide. With
aging, a gradual loss of bone mass results in osteopenia and oste-
oporosis. Osteoporosis, falling, and related fragile fracture have
been identiﬁed as being a serious public health issue. The cumu-
lative lifetime fracture risk for a 50-year woman with osteoporosis
is as high as 60%1. For elderly people in residential care facilities or
nursing homes, the annual risk of fall is > 50%2. The most common
sites of osteoporotic fracture are the hip, humerus, wrist, and
spine3. Among these fractures, hip fracture is life-threatening4.
Approximately 5e20% of these patients die within 1 year, and 50%afﬁliations with or ﬁnancial
le future, any organization or
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tric Emergency & Critical Care Meof survivors have difﬁculties performing daily activities and, thus,
need extra care5. The direct medical expenditure for nonfatal fall-
related fractures is approximately $12 billion in 20136. Many el-
ders who fall have high incidence of recurrent falls7. They will
develop a fear of fall and tend to limit their activities, resulting in
reduced mobility and loss of physical ﬁtness and bone mass.
Effective prevention of osteoporotic fracture needs compre-
hensive management, including healthy lifestyle, regular exercise,
adequate nutrition, safe living environment, and reducing medi-
cation dosage. Calcium and vitamin D supplements have long been
recognized as the cornerstones for prevention and management of
osteoporosis and fractures. Calcium is a major constituent of bone.
It would make sense that calcium supplementation or the con-
sumption of calcium-rich foods was helpful in maximizing peak
bone mass, retaining acquired bone mass, and thus reducing the
risk of osteoporosis. A recent study has shown that women took
calcium supplements for about half of their daily calcium require-
ment to meet the National Academy of Sciences guidelines, some
even exceeding daily recommended intakes8.
Vitamin D, a group of hormones rather than vitamins, is majorly
synthesized in the skin during exposure to UV B and less absorbed
from the diet. 25-hydroxyvitamin D [25(OH)D], the major circu-
lating and storagemetabolite, is viewed as themost useful maker todicine. Published by Elsevier Taiwan LLC. All rights reserved.
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[1,25(OH)2D], the biologically activemetabolite, enhances intestinal
calcium absorption and interacts with the parathyroid hormone to
help maintain calcium homeostasis between the blood and
bones (Fig. 1). 1,25(OH)2D also affects neuromuscular and immune
function. The Institute of Medicine Committee, an American
non-governmental organization established in 1970, examined
the totality of the available evidence and concluded that calcium
absorption reaches near maximum at serum 25OHD levels of
8e20 ng/mL9.
Beyond the role of calcium and vitamin D supplements in
maintaining bone health, emerging evidence suggests that calcium
with or without vitamin D supplementation might have potential
adverse effects in the general population, such as cardiovascular
events10e15, sudden death, cancer, or urinary tract stone16e18.
Although several studies showed a reduction in cancer incidence
for those taking vitamin D or vitamin D plus calcium12,18e22, theFig. 1. Schematic diagram of synthesis of vitamin D and regulation of calcium homeostasis.
absorbed from the diet. 25-hydroxyvitamin D [25(OH)D], the major circulating and storage
1,25-dihydroxyvitamin D [1,25(OH)2D], is generated in the kidney. 1,25(OH)2D increases the
effects on parathyroid cells to help maintain calcium homeostasis between the blood and bevidence is insufﬁcient to make a conclusion about the beneﬁts or
harms of vitamin D or vitamin D plus calcium supplementation for
cancer prevention18,23. The inconsistent results of studies and
meta-analysis of calcium and vitamin D supplements and risk of
cardiovascular events raised the question as to whether the car-
diovascular adverse effect is large enough to abrogate the beneﬁcial
effects on fractures. In this article, we review current evidence of
calcium and vitamin D supplements on bone health and possible
adverse outcomes to encourage clinicians to think of the beneﬁts
and possible adverse effects prior to advising calcium and vitamin
D supplementation for the prevention of osteoporotic fracture.
2. Recent evidence of effect of calcium and vitamin D
supplements on bone health
Because the primary goal of the calcium and vitamin D sup-
plementation is the prevention of osteoporotic fracture, theVitamin D is majorly synthesized in the skin during exposure to UV radiation and less
form of vitamin D, is converted in the liver. The biologically active form of vitamin D,
efﬁciency of intestinal calcium absorption and has been shown to have antiproliferative
ones. PTH ¼ parathyroid hormone.
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fracture outcomes. Although few review articles have reported that
taking vitamin D alone is unlikely to prevent fracture and vitamin D
plus calcium did appear to reduce risk of hip fractures among
institutionalized adults24,25, most trials and meta-analysis of
vitamin Dwith or without calcium supplement showed statistically
signiﬁcant reduction in fractures. Vitamin D doses of 400 IU and
lower did not show antifracture efﬁcacy. There was a dos-
eeresponse relationship between supplemental vitamin D and
fracture reduction26. Oral vitamin D dose of 700e800 IU/day, alone
or in combination with calcium supplementation, reduced the risk
of hip fracture [n ¼ 5572; pooled relative risk (RR) 0.74; 95% con-
ﬁdence interval (CI) 0.61e0.88) and any nonvertebral fracture
(n ¼ 6098; pooled RR 0.77; 95% CI 0.68e0.87) in ambulatory or
institutionalized elderly persons (age  60 years)27. For higher
doses of vitamin D (median, 800 IU daily; range, 792e2000;
n ¼ 3966 individuals), the reduction rate was 30% [hazard ratio
(HR) 0.70; 95% CI 0.58e0.86; p < 0.001) for hip fractures and 14%
(HR 0.86; 95% CI 0.76e0.96; p ¼ 0.007) for nonvertebral fractures.
The effect was independent of age, sex, additional calcium intake,
and type of dwelling28. However, extremely high doses of vitamin D
were not consistently associated with greater beneﬁts and might
led to potential adverse effects. An annual intramuscular injection
of 300,000 IU vitamin D2 was ineffective in reducing nonvertebral
fractures29. Furthermore, an annual oral administration of
500,000 IU D3 resulted in an increased risk of falls (RR 1.15; 95% CI
1.02e1.30; p ¼ 0.03) and fractures (RR 1.26; 95% CI 1.00e1.59;
p ¼ 0.047)30.
Data on the effects of calcium supplementation on bone mineral
density and fracture rates in the general population are conﬂicting.
Calcium and calcium plus vitamin D (CaD) were associated with a
reduction in bone loss17,31,32 and fracture risk31,33. On the contrary,
Grant et al34 reported that the incidence of new, low-trauma frac-
tures did not differ signiﬁcantly: between with the use of oral cal-
cium (1000mg) and placebo; between oral vitamin D3 (800 IU) and
placebo; or between combined Vitamin D (800 IU) and calcium
(1000 mg) supplements and placebo. Another two meta-ana-
lyses17,35 and the US Preventive Services Task Force's recommenda-
tions24 conﬁrmed these ﬁndings. However, some researchers
performed several meta-analyses with subgroup stratiﬁcation and
foundthat the fracture risk reductionwas signiﬁcantlygreater in trial
with a high adherence rate of calcium and vitamin D supplementa-
tion17,31,36. The fracture risk reductions were signiﬁcantly greater
amongwomenwho took at least 80%of their study supplements (HR
0.71; 95% CI 0.52e0.97)17 or followed  5 years of treatment (HR
0.65; 95% CI 0.44e0.98)36, and among participants with compliance
rate of  80% (RR 0.76; 95% CI 0.67e0.86; p ¼ 0.002)31. The anti-
fracture efﬁcacy was better in individuals who were older than 70
years, lived in institutions18,25,31,37, and had low bodyweight31.
In summary, calcium and CaD were associated with a reduction
in bone loss. Vitamin D doses of 400 IU and lower did not show
antifracture efﬁcacy. A daily oral administration of 800e2000 IU
vitamin D, with or without calcium supplementation, may reduce
the risk of hip fracture. The fracture risk reductions were signiﬁ-
cantly greater among participants with high compliance rate and
longer administration.
3. Potential adverse outcomes of calcium and vitamin D
Bolland et al10e12, Reid and Bolland13, and Reid et al14,15 reported
the possible increased risk of adverse cardiovascular events asso-
ciated with calciumwith or without vitamin D supplementation. A
5-year randomized controlled trial found possible increases in rates
of myocardial infarction (MI) in healthy postmenopausal women
allocated to calcium supplementation (RR 2.12; 95% CI 1.01e4.47;p ¼ 0.047)11. The following studies reported similar ﬁndings that
calcium supplements with or without vitamin D increased the risk
of MI10,12,38 and the composite end point of MI or stroke (RR 1.15;
95% CI 1.03e1.27; p ¼ 0.009)12. The associations between calcium
supplementation and CVDmortality were null10e12,38. An increased
risk of MI was more pronounced for calcium supplement only users
(HR 2.39; 95% CI 1.12e5.12)38. In comparison with calcium sup-
plementation, a moderately higher dairy calcium intake
(mean¼ 466mg/day) signiﬁcantly reducedMI risk (HR 0.68; 95% CI
0.50e0.93)38. The possible mechanism of the adverse effect of
calcium supplements on MI risk might be related to the acute in-
crease in serum calcium levels after ingestion of calcium supple-
ments. Highenormal serum calcium levels have been known to be
associated with an increased risk of vascular calciﬁcation and car-
diovascular events.
Randomized controlled trials on vitamin D effects on cardio-
vascular risk factors showed inconsistent results. Although few
meta-analysis of randomized controlled trials indicated a signiﬁ-
cant decrease in mortality with using vitamin D supplements39e42,
the majority of the researches did not report statistically signiﬁcant
associations between vitamin D and cardiovascular events, stroke,
and death23,36,43e45. Moreover, higher serum 25(OH)D levels were
not necessarily better and U-shaped associations of some outcomes
related to vitamin D were observed23,46e49.
Findings on calcium and vitamin D intake and cancer are
inconsistent. In the Women's Health Initiate (WHI) trial of CaD
(1000mg calcium and 400 IU vitamin D daily), Bolland et al50 found
women who were not taking personal calcium or vitamin D sup-
plement at the time ofWHI enrollment, CaD signiﬁcantly decreased
the risk of total cancer (HR 0.86; 95% CI 0.78e0.96; p ¼ 0.007),
breast cancer (HR 0.82; 95% CI 0.70e0.97; p ¼ 0.021), and invasive
breast cancers (HR 0.80; 95% CI 0.66e0.96; p ¼ 0.015) and
nonsigniﬁcantly decreased the risk of in situ breast cancer and
colorectal cancer. In women who were taking personal calcium or
vitamin D supplements, CaD did not change cancer risk. However,
Prentice et al36 reanalyzed theWHI data further and stated that the
statistical reduction in breast cancer risk and total invasive cancer
risk among CaD users was nominal. Several meta-analyses and
clinical trials revealed allocation to calcium, vitamin D, or the
combination did not alter the risk of total cancer19,51, colorectal
cancer51,52, breast cancer51e54, and cancer-related mortality19,51.
Signiﬁcant treatment interactions on incident cancer were found
for a family history of cancer20, highest dose of vitamin D20,52,55,
and smoking20.
Calcium is the major component of 85% of kidney stones. Uri-
nary tract stone occurrence was more common inwomenwho took
supplemental CaD than placebo (HR 1.17; 95% CI 1.02e1.34) in the
WHI trial17,56, consistent with previous research16. In contrast with
adverse effects of calcium supplements on renal calculi, dietary
calcium may lower new kidney stone formation16 through binding
of dietary oxalate and calcium in the intestinal lumen that de-
creases urine calcium oxalate supersaturation.
In summary, consumption of calcium from supplements might
increase the risk of adverse cardiovascular events and urinary tract
stones, but not from diet. No statistically signiﬁcant associations
between vitamin D and cardiovascular events, stroke, and death
were reported. The available evidence is still insufﬁciently robust to
draw conclusions the inﬂuence of calcium/vitamin D intake on
cancer risk.
4. Current recommendations and daily intakes of calcium
and vitamin D
After reviewing > 1000 higher-quality studies, the Institute of
Medicine updated the estimated average requirement (intake that
Table 1
Dietary reference intakes for calcium and vitamin D for adults aged  51 years.
Institute of Medicine recommendations for bone health in general populationa
Life stage group Calcium Vitamin D
EAR (mg/d) RDA (mg/d) UL (mg/d) EAR (IU/d) Serum 25(OH)Db
for the EAR
(ng/mL)




51e70 y (M) 800 1000 2000 400 16 600 20 4000
51e70 y (F) 1000 1200 2000 400 16 600 20 4000
71þ y (MþF) 1000 1200 2000 400 16 800 20 4000
Endocrine Practice Guidelines Committee recommendations for patients at risk for vitamin D deﬁciency
Life stage group Vitamin D
Daily requirement
(IU/d)
Target serum 25(OH)D (ng/mL) UL
(IU/d)
51e70 y (M) 1500e2000 30 10,000
51e70 y (F) 1500e2000 30 10,000
71þ y (MþF) 1500e2000 30 10,000
EAR¼ estimated average requirement for intake that meets the needs of 50% of the North American population (median); F¼ female; M¼male; RDA¼ recommended dietary
allowance for intake that meets the needs of 97.5% of the North American population; UL ¼ tolerable upper intake level, above which there is risk of adverse events. The UL is
not intended as a target intake (no consistent evidence of greater beneﬁt at intake levels more than the RDA).
a The recommendation was established by the Institute of Medicine for the needs of the North American population, released on November 30, 2010.
b Measure of serum 25-hydroxyvitamin D (25OHD) level corresponding to the EAR and covering the needs of 50% of the North American population.
c Measure of serum 25OHD level corresponding to the RDA and covering the needs of at least 97.5% of the population.
Table 2
Natural sources of vitamin D and calcium.
Sources Vitamin D content
Sunlight/UVB radiation About 3000 IU ¼ Exposure of
the arms and legs in bathing
suit or shorts and short sleeved
shirt without the use of sunscreen
products to 0.5 minimal erythemal
dose
Salmon
fresh, wild (100 g) 600e1000 IU
fresh, farmed (100 g) 100e250 IU
Cod liver oil (5 mL) 400e1000 IU
Sardines, canned (100 g) ~300 IU
Mackerel, canned (100 g) ~250 IU
Tuna, canned (102 g) About 230 IU
Shiitake mushrooms
Sun-dried (100 g) About 1600 IU
Fresh (85 g) About 100 IU
Egg yolk About 20 IU
Sources Calcium content (mg)
Yogurt (236 mL) 450 mg
Tofu prepared with calcium (118 mL) 435 mg
Sardines (85 g) 370 mg
Milk (240 mL) 300 mg
Cheese (28 g) 195e335 mg (higher calcium in
hard cheese)
Soy milk (240 mL) 300 mg
Figs, dried, uncooked (236 mL) 300 mg
Mackerel, canned (85 g) 250 mg
Spinach, cooked (236 mL) 240 mg
Soybeans, boiled (236 mL) 200 mg
Broccoli, cooked (236 mL) 180 mg
Arugula, raw (236 mL) 125 mg
Almonds, toasted unblanched (28 g) 80 mg
Orange (1 medium) 60 mg
Kiwi, raw (236 mL) 50 mg
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etary allowance (RDA; intake that covers needs of  97.5% of the
population) intakes for calcium and vitamin D of North American
population on November 30, 20109,48 (Table 1). The Committee
concluded that available scientiﬁc evidence supports a key role of
calcium and vitamin D in skeletal health, consistent with a cause-
and-effect relationship. However, for their roles in cancer,
including cardiovascular disease, diabetes, and autoimmune dis-
orders, the evidence was inconsistent. The RDA for calcium is
1000 mg/day for men aged 51e70 years, and 1200 mg/day for
women aged 51e70 years and for women andmen aged 71 years.
The RDA for vitamin D was 600 IU/day for adults aged 51e70 years,
and 800 IU/day for adults aged 71 years and over tomaintain serum
25(OH)D at or above 20 ng/mL.
On the promise that vitamin D deﬁciencies are common among
all age groups and that few foods contain vitamin D, the Endocrine
Society prefers 30 ng/mL (75mM) of 25(OH)D as the target level for
maximal beneﬁts and recommends daily supplements of
1500e2000 IU are required for US, Canadian, and European
adults57 (Table 1), although the Institute of Medicine committee
disagree with these viewpoints58.
In 2014, the American Geriatrics Society stated that clinicians
are strongly advised to recommend vitamin D supplementation of
at least 1000 IU/day with calcium to older adults (age > 65 years)
residing in the community or institutional settings to reduce the
risk of fractures and falls. A serum 25(OH)D concentration of 30 ng/
mL (75mM) should be a minimal goal for older adults, particularly
for frail adults, who are at higher risk of falls, injuries, and fractures.
An average daily vitamin D input of 4000 IU from all sources is
required to result in 92% of older adults in the United States
achieving target 25(OH)D levels. Routine laboratory testing for
25(OH)D serum concentrations before supplementation begins or
for safety or efﬁcacy when supplementation is within the recom-
mended limits are not necessary. Clinicians may monitor 25(OH)D
after 4 months of vitamin D3 supplementation to conﬁrm that
appropriate levels have been achieved46.
Increasing dietary calcium should be considered ﬁrst. When
adequate dietary calcium intake cannot be achieved or patients are
unwilling to do so, calcium supplement tablets could be used.
Calcium carbonate is bioavailable when takenwith a meal. Calciumcitrate is recommended for individuals with a history of renal
stones59. Very few foods are naturally rich in vitamin D. Additional
vitamin D supplements are usually needed to meet the recom-
mendations for daily intake. Natural sources of vitamin D and cal-
cium are listed in Table 2.
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Calcium and vitamin D play a key role in skeletal health. How-
ever, the evidence of potential adverse outcomes of calcium and
vitamin D supplementation is inconsistent. Although emerging
evidence suggests that calcium with or without vitamin D sup-
plementationmight increase the risk of myocardial infarction, most
experts conclude that individuals who do not obtain sufﬁcient
intake of calcium and vitamin D from their diet should not be
advised to avoid using calcium and vitamin D supplementation60.
While the primary purpose of supplementation is to reduce the risk
of fractures, vitamin D supplementation of at least 1000 IU/day
with calcium of 1000e1200 mg/day to older adults is recom-
mended, particularly to frail adults46,48. It seems that vitamin D has
a biphasic effect for bone mass and U-shaped associations of some
outcomes23,47e49. The supplementation levels of vitamin D need
adjustments for sun exposure, skin pigmentation, and high body
mass. Clinicians should review patient's calcium and vitamin D
intake from all sources and individualize decision making to the
speciﬁc patient or situation.References
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